Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›
Research›
Non-Profits›
Ndri - National Disease Research Interchange
AddedFeb 15, 2024
UpdatedJun 18, 2026
Ndri - National Disease Research Interchange

Ndri - National Disease Research Interchange

Operating

National Disease Research Interchange: Your source for human tissues, cells, and organs for research.

Founded
1980
Location
Philadelphia, PA, US
Overview
Compare
Employees
Website

Founded in 1980, the National Disease Research Interchange (NDRI) is dedicated to advancing biomedical and bioscience research by providing high-quality human tissues, cells, and organs to researchers worldwide. Their core mission is to facilitate scientific breakthroughs by ensuring that researchers have access to the human biospecimens necessary for their work. NDRI partners with academic institutions and corporate investigators to meet the specific needs of demanding research projects, thereby contributing to advancements in healthcare and science.

NDRI has established itself as a critical resource in the research community, distributing biospecimens to hundreds of investigators globally. Notable affiliated individuals include leading scientists and researchers who rely on NDRI's resources for their studies. The organization has received support from various government and private sector entities, reflecting its importance in the field. NDRI's impact is evident in the numerous scientific advancements and healthcare improvements that have stemmed from research utilizing their biospecimens.

Quick Facts

When was Ndri - National Disease Research Interchange founded?

Ndri - National Disease Research Interchange was founded in 1980.

Where is Ndri - National Disease Research Interchange's headquarters located?

Ndri - National Disease Research Interchange's headquarters is located in Philadelphia, PA, US.

When was Ndri - National Disease Research Interchange's last funding round?

Ndri - National Disease Research Interchange's most recent funding round was for $3.7M (USD) in September 2023.

How much has Ndri - National Disease Research Interchange raised to-date?

As of Sep 6, 2023, Ndri - National Disease Research Interchange has raised a total of $18.4M (USD).

How many employees does Ndri - National Disease Research Interchange have?

Ndri - National Disease Research Interchange has 80 employees as of Feb 4, 2024.

Classification

Ownership
  • Non-profit
Technology
  • Biotech
Geographic Exposure
  • Global
Customer
  • Non-Profit
Main Product
  • Biospecimens
  • Tissues
Tags
  • Biotech
NAICS
  • 610000Educational Services
  • 611300Colleges, Universities, and Professional Schools
  • 611310Colleges, Universities, and Professional Schools
  • 611000Educational Services
SIC
  • 8220Colleges, Universities, Professional Schools, And Junior Colleges
  • 8221Colleges, Universities, And Professional Schools
  • 8200Educational Services
ISIC
  • 7320Market research and public opinion polling
Show 12 more industry codes
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541910Marketing Research and Public Opinion Polling
  • 620000Health Care and Social Assistance
  • 541000Professional, Scientific, and Technical Services
  • 541900Other Professional, Scientific, and Technical Services
SIC
  • 8732Commercial Economic, Sociological, And Educational Research
  • 8000Health Services
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8290Schools And Educational Services, Not Elsewhere Classified
  • 8730Research, Development, And Testing Services
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified